Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Advanced Therapeutics is Scopus-indexed (Q2, CiteScore 4.9), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Wiley-Blackwell Publishing Ltd.
Checked against the index lists dated .
ISSN 2366-3987Verify ISSN ↗
Publisher: Wiley-Blackwell Publishing Ltd
Cost to publish: About US$4,430 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (miscellaneous) | 124 / 466 | 73rd | Q2 |
| Biochemistry (medical) | 28 / 78 | 64th | Q2 |
| Pharmaceutical Science | 71 / 191 | 63rd | Q2 |
| Pharmacology (medical) | 104 / 278 | 62nd | Q2 |
| Genetics (clinical) | 40 / 100 | 60th | Q2 |
| Pharmacology | 148 / 328 | 55th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2018–present, best quartile Q2, CiteScore 4.9.
Advanced Therapeutics is Q2 in Medicine (miscellaneous) (rank 124 of 466), Q2 in Biochemistry (medical) (rank 28 of 78) and Q2 in Pharmaceutical Science (rank 71 of 191), by CiteScore 2025. It is ranked in 6 subject areas in all.
Advanced Therapeutics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.9, which places it in quartile Q2 at the 73rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.651, quartile Q2, with an H-index of 54.
The publisher lists an article processing charge of about US$4,430 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Advanced Therapeutics is published by Wiley-Blackwell Publishing Ltd. Its ISSN is 2366-3987.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Advanced Therapeutics has an h-index of 58 and a 2-year mean of 3.02 citations per paper (OpenAlex). Its Scopus CiteScore is 4.9, quartile Q2. On 2-year citations it ranks #100 of 451 Scopus journals in Medicine (miscellaneous).
Advanced Therapeutics published 167 papers in 2025; its busiest recent year was 2023 with 212. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from India (23.4%), China (19.9%) and United States (14.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.